1. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C, García-Luna Y González-Rubio M, Gayosso-de-Lucio JA, Morales-González JA. Hepatoprotective effect of silymarin. World J Hepatol. 2014 Mar 27;6(3):144-9. doi: 10.4254/wjh.v6.i3.144. PMID: 24672644; PMCID: PMC3959115.
2. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011 May 14;17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288. PMID: 21633595;
3. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010 Oct;24(10):1423-32. doi: 10.1002/ptr.3207. PMID: 20564545.
4. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–63.
5. Vaid M, Katiyar SK. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol. 2010 May;36(5):1053-60. doi: 10.3892/ijo_00000586. PMID: 20372777; PMCID: PMC2852174.
6. Dashti-Khavidaki S, Shahbazi F, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci. 2012;15(1):112-23. doi: 10.18433/j3f88s. PMID: 22365093.
7. Singh M, Kadhim MM, Turki Jalil A, Oudah SK, Aminov Z, Alsaikhan F, et al. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. Cancer Cell Int. 2023 May 10;23(1):88. doi: 10.1186/s12935-023-02936-4. PMID: 37165384; PMCID: PMC10173635.
8. Zalat Z, Kohaf N, Alm El-Din M, Elewa H, Abdel-Latif MMM. Silymarin: A promising cardioprotective agent. Azhar Int J Pharm Med Sci. 2021;1(1):13–21.
9. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010 Feb;125(2):196-218. doi: 10.1016/j.pharmthera.2009.10.002. Epub 2009 Oct 27. PMID: 19874849.
10. Adão R, de Keulenaer G, Leite-Moreira A, Brás-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol. 2013 May;32(5):395-409. English, Portuguese. doi: 10.1016/j.repc.2012.11.002. Epub 2013 Apr 24. PMID: 23623503.
11. Razavi BM, Karimi G. Protective effect of silymarin against chemical-induced cardiotoxicity. Iran J Basic Med Sci. 2016 Sep;19(9):916-923. PMID: 27803777; PMCID: PMC5080420.
12. El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008 Jul;46(7):2422-8. doi: 10.1016/j.fct.2008.03.033. Epub 2008 Apr 7. PMID: 18487002.
13. Patel N, Joseph C, Corcoran GB, Ray SD. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):143-52. doi: 10.1016/j.taap.2010.02.002. Epub 2010 Feb 6. PMID: 20144634.
14. Rašković A, Stilinović N, Kolarović J, Vasović V, Vukmirović S, Mikov M. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13. doi: 10.3390/molecules16108601. PMID: 21993249; PMCID: PMC6264541.
15. Arozal W, Suyatna FD, Juniantito V, Rosdiana DS, Amurugam S, Aulia R, et al. The Effects of Mangiferin (Mangifera indica L) in Doxorubicin-induced Cardiotoxicity in Rats. Drug Res (Stuttg). 2015 Nov;65(11):574-80. doi: 10.1055/s-0034-1394457. Epub 2014 Nov 26. PMID: 25426848.
16. Afsar T, Razak S, Batoo KM, Khan MR. Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats. BMC Complement Altern Med. 2017 Dec 29;17(1):554. doi: 10.1186/s12906-017-2061-0. PMID: 29284479; PMCID: PMC5747129.
17. Psotová J, Chlopcíková S, Grambal F, Simánek V, Ulrichová J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res. 2002 Mar;16 Suppl 1:S63-7. doi: 10.1002/ptr.811. PMID: 11933142.
18. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019 Jul;88:102925. doi: 10.1016/j.bioorg.2019.102925. Epub 2019 Apr 11. PMID: 31003078.
19. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006 Mar;53(3):278-86. doi: 10.1016/j.phrs.2005.12.005. Epub 2006 Jan 24. PMID: 16436331.
20. Afsar T, Razak S, Almajwal A, Shabbir M, Khan MR. Evaluating the protective potency of Acacia hydaspica R. Parker on histological and biochemical changes induced by Cisplatin in the cardiac tissue of rats. BMC Complement Altern Med. 2019 Jul 23;19(1):182. doi: 10.1186/s12906-019-2575-8. Erratum in: BMC Complement Med Ther. 2020 Oct 27;20(1):326. PMID: 31337380; PMCID: PMC6651963.
21. El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011 Jan 10;650(1):335-41. doi: 10.1016/j.ejphar.2010.09.085. Epub 2010 Oct 29. PMID: 21034734.
22. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, ed. Connect Applet Lange. 2014;4:141–2.
23. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999 Sep;290(3):1375-83. PMID: 10454517.
24. Momeni A, Hajigholami A, Geshnizjani S, Kheiri S. Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study. J Clin Diagn Res. 2015 Apr;9(4):OC11-3. doi: 10.7860/JCDR/2015/12776.5789. Epub 2015 Apr 1. PMID: 26046020; PMCID: PMC4437094.
25. Mahi-Birjand M, Karimzadeh I, Zarban A, Abdollahpour-Alitappeh M, Saadatjoo SA, Ziaee M. Protective effects of silymarin on gentamicin-induced nephrotoxicity in infectious patients: a randomized double blinded placebo-controlled clinical trial. Pharm Sci. 2020;26(3):287–95. doi:10.34172/PS.2020.33
26. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988 Apr;33(4):900-11. doi: 10.1038/ki.1988.83. PMID: 3290565.
27. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011 Jan;79(1):33-45. doi: 10.1038/ki.2010.337. Epub 2010 Sep 22. PMID: 20861826.
28. Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther. 2007 Oct;30(5):477-81. doi: 10.1111/j.1365-2885.2007.00901.x. PMID: 17803742.
29. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. doi: 10.2215/CJN.04800908. PMID: 19218475.
30. Zima T, Kameníková L, Janebová M, Buchar E, Crkovská J, Tesar V. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail. 1998 May;20(3):471-9. doi: 10.3109/08860229809045136. PMID: 9606735.
31. Satyanarayana PS, Singh D, Chopra K. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. Methods Find Exp Clin Pharmacol. 2001 May;23(4):175-81. doi: 10.1358/mf.2001.23.4.634641. PMID: 11676225.
32. Guzel S, Sahinogullari ZU, Canacankatan N, Antmen SE, Kibar D, Coskun Yilmaz B. Potential renoprotective effects of silymarin against vancomycin-induced nephrotoxicity in rats. Drug Chem Toxicol. 2020 Nov;43(6):630-636. doi: 10.1080/01480545.2019.1584208. Epub 2019 Mar 12. PMID: 30862206.
33. AbouZid S. Silymarin, natural flavonolignans from milk thistle. Phytochem Glob Perspect Their Role Nutr Heal Rijeka InTech. 2012;p255-272.
34. Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 1995 Dec;109(6):1941-9. doi: 10.1016/0016-5085(95)90762-9. PMID: 7498660.
35. Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol. 1986 Feb 1;35(3):538-41. doi: 10.1016/0006-2952(86)90233-9. PMID: 3004503.
36. Bergheim I, McClain CJ, Arteel GE. Treatment of alcoholic liver disease. Dig Dis. 2005;23(3-4):275-84. doi: 10.1159/000090175. PMID: 16508292; PMCID: PMC2636549.
37. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem. 1999 Oct;32(7):519-36. doi: 10.1016/s0009-9120(99)00052-1. PMID: 10614715.
38. Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol. 1990 Aug;10(4):275-9. doi: 10.1002/jat.2550100408. PMID: 1975258.
39. Wang M, La Grange L, Tao J, Reyes E. Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage. Fitoter. 1996;67(2):166–71.
40. Vogel G, Tuchweber B, Trost W, Mengs U. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol. 1984 May;73(3):355-62. doi: 10.1016/0041-008x(84)90087-5. PMID: 6719456.
41. Sandoval M, Lazarte K, Arnao I. Antioxidant liver protection of Vitis vinifera L.(grape) skin and seed. In: Anales de la Facultad de Medicina. UNMSM. Facultad de Medicina; 2008. p. 250–9.
42. Kwon DY, Jung YS, Kim SJ, Kim YS, Choi DW, Kim YC. Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver. Planta Med. 2013 Aug;79(12):997-1002. doi: 10.1055/s-0032-1328704. Epub 2013 Jun 27. PMID: 23807810.
43. Marjani M, Baghaei P, Kazempour Dizaji M, Gorji Bayani P, Fahimi F, Tabarsi P, et al. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iran J Pharm Res. 2016 Winter;15(1):247-52. PMID: 27610165;
44. Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond). 2008 Jul 5;5:18. doi: 10.1186/1743-7075-5-18. PMID: 18601745; PMCID: PMC2491620.
45. Marjani M, Fahim F, Sadr M, Dizaji MK, Moniri A, Khabiri S, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol from bed to bench. 2019;12(2):138.
46. Chlopcíková S, Psotová J, Miketová P, Simánek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res. 2004 Feb;18(2):107-10. doi: 10.1002/ptr.1415. PMID: 15022159.
47. Hagag AA, El Shehaby WA, El-Abasy AI, Mabrouk MM. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia. Infect Disord Drug Targets. 2019;19(2):133-140. doi: 10.2174/1871526518666180803141827. PMID: 30073931.
48. Abdelmeguid NE, Chmaisse HN, Zeinab NA. Protective effect of silymarin on cisplatin-induced nephrotoxicity in rats. Pak J Nutr. 2010;9(7):624–36.
49. Al-Sa’aidi JAA. Protective effect of Silymarin against cyclosporine nephrotoxicity in male rats. Al-Qadisiyah J Vet Med Sci. 2019;18(1):39–46.
)